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Abstract Mucopolysaccharidoses (MPS) are inherited
metabolic diseases caused by mutations in genes coding for
lysosomal enzymes involved in the degradation of gly-
cosaminoglycans (GAGs). Dysfunction of any of these
enzymes results in the accumulation of GAGs, which leads
to severe clinical symptoms and significantly shortened life
span. Several kinds of therapies have been proposed to treat
MPS, including bone marrow or stem cell transplantation,
enzyme replacement therapy, and gene therapy. Another
option is substrate reduction therapy (SRT), in which
synthesis of GAGs is inhibited. Recent studies employing
in vitro and animal models suggested that this therapy may
be efficient in decreasing levels of GAGs in MPS cells,
including those bearing two null alleles of the affected
gene. Results of behavioral tests in animals as well as some
preliminary clinical observations with pediatric patients
corroborated the suggestions about possible efficacy of
SRT in MPS treatment, including brain functions. Efficient
reduction of GAG levels in MPS cells homozygous for null
mutations may be intriguing in the commonly accepted
scheme of SRT mode of action. In this paper, we propose
an explanation of this phenomenon, based on already
known facts. Thus, we suggest that SRT may lead to
reduction of GAG levels in MPS cells due to inhibition of
efficiency of GAG synthesis combined with (a) any read-
through of the stop codon, (b) dilution of already
accumulated GAGs due to cell growth followed by cell
divisions, and (c) action of endoglycosidases degrading
GAGs, e.g., heparanase, in combination with functional
GAG-specific hydrolases.
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Introduction: Overview on Mucopolysaccharidoses
Mucopolysaccharidoses (MPS) are a group of lysosomal
storage diseases (LSD), inherited metabolic disorders
caused by dysfunctions of enzymes involved in the deg-
radation of certain compounds or their transport through
lysosomal membranes (Schultz et al. 2011). MPS are
characterized by accumulation of glycosaminoglycans
(GAGs) (formerly called mucopolysaccharides) caused by
mutations in genes coding for enzymes involved in the
degradation of GAGs (for a review, see Neufeld and Mu-
enzer 2001). Impaired hydrolysis of these compounds
[particularly dermatan sulfate (DS), heparan sulfate (HS),
or keratan sulfate (KS)] results in their storage in virtually
all cells of the affected organism (Dorfman 1964; Van
Gemund et al. 1971; Benson et al. 1972; Cain et al. 1977;
for a review, see Neufeld and Muenzer 2001). This causes
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a progressive damage of tissues, leading to severe dys-
functions of various organs, including the heart, respiratory
system, bones, joints, and central nervous system (CNS). In
most cases, MPS are fatal diseases, with severe symptoms
and significantly shortened life span, though patients with
milder forms have been described (summarized by Neufeld
and Muenzer 2001).
Depending on the nature of lacking or defective enzyme
and the kind(s) of stored GAG(s), 11 types and subtypes of
MPS have been distinguished. Interestingly, despite the
fact that a defect in particular enzyme is responsible for
particular MPS type, an enormously large variability in the
spectrum and severity of symptoms occurs in each MPS
type (Neufeld and Muenzer 2001). This contributes sig-
nificantly to serious problems with prediction of progress
and severity of the disease in newly diagnosed patients, as
well as with establishing adequate tests for monitoring
efficacy of treatments with newly developed therapies for
MPS (Wegrzyn et al. 2004).
Current Therapeutic Options for MPS
Despite extensive studies on the development of novel
therapies for MPS are being conducted, only a couple of
therapeutic options is currently available to patients as
approved procedures. These are bone marrow (BMT) or
hematopoietic stem cells’ (HSCT) transplantations and
enzyme replacement therapy (ERT). Since placebo-con-
trolled clinical trials with BMT or HSCT for MPS were not
performed, our knowledge on this type of treatment comes
mostly from anecdotal descriptions. Nevertheless, it
appears that stabilization of the disease or slowing down of
the disease progress can be obtained after transplantation in
some MPS types, especially MPS I (de Ru et al. 2011).
However, it has been suggested that some other MPS types,
like MPS III, are generally significantly less responsive to
BMT and HSCT (Lau et al. 2010 and references therein).
Moreover, positive results in MPS I can be expected only if
transplantation was performed in relatively young patients,
i.e., below 2.5 years of age (summarized by de Ru et al.
2011).
ERT is currently used in a clinical practice for only three
MPS types: I, II and VI (Clarke 2008; Wraith 2008; Prasad
and Kurtzberg 2010). Unfortunately, despite an unques-
tioned success of ERT in treating of some MPS symptoms
and halting the progress of deterioration of some somatic
organs (though a high variability of efficacy occurs in
different patients), this therapy also has important restric-
tions, like a highly limited ability of the intravenously
administered recombinant enzyme to cross the blood–
brain-barrier and thus, a lack of efficacy in the treatment of
neurological symptoms (Wraith 2008).
Intrathecal ERT has been tested in some patients with
quite encouraging results, especially in the treatment of
spinal cord compression (Munoz-Rojas et al. 2008, 2010);
however, these experimental treatments were performed
with either adult or non-neuronopathic pediatric patients. In
this light, it is important that there are questions about
safety of this procedure in children, especially those
expressing hyperactivity and being on a high risk during
anesthetic procedures, like most pediatric MPS patients.
One should also consider immunological problems of ERT,
i.e., inactivation of the therapeutic enzyme by antibodies
produced by a patient, especially if two null alleles of the
defective gene occur in his/her genome (Ponder 2008).
Although gene therapy remains a hope for MPS patients,
it is still a treatment under development (Cotrim and Baum
2008; Beck 2010; Anson et al. 2011). Therefore, there is a
continuous need for alternative therapies, which could be
helpful for patients suffering from various MPS types.
Substrate Reduction Therapies (SRPs) for MPS
Since MPS are caused by the accumulation of GAGs due to
their inefficient degradation, it was assumed that a decrease
in efficiency of synthesis of these compounds might lead to
slowing down the storage process and improvement of cell
functions (Wegrzyn et al. 2004). If working ideally, this
kind of treatment could restore the balance between GAG
synthesis and degradation, already lost in the MPS cells.
This therapeutic concept is known as SRT. In fact, SRT has
been introduced as a therapeutic option for treatment of
other LSD, such as Gaucher disease (Weinreb et al. 2005)
or Niemann-Pick C disease (Patterson et al. 2007). The
product called miglustat (N-butyldeoxynojirimycin), an
inhibitor of glucosylceramide synthase, has been approved
as a drug for the above-mentioned diseases. Since it slows
down the production of glycosphingolipids, it should be
effective in reducing storage of these compounds.
Although positive effects of such treatment in clinical trials
were reported (Elstein et al. 2004; Pastores et al. 2005), its
efficacy in Gaucher disease has recently been questioned
(Tylki-Szymanska et al. 2011; Machaczka et al. 2012).
There are various possible means of reducing the effi-
ciency of GAG synthesis. The most straight-forward
method is the use of specific chemical inhibitors of GAG
synthesis. However, finding of non-toxic inhibitors of
enzymes involved in GAG production is extremely diffi-
cult, and was not successful to date. Therefore, a search for
compounds inhibiting GAG synthesis indirectly has been
performed (for review, see Jakobkiewicz-Banecka et al.
2007).
Rhodamine B ([9-(2-carboxyphenyl)-6-diethylamino-3-
xanthenylidene]-diethylammonium chloride), a compound
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used as a staining fluorescent dye, has been demonstrated
to reduce GAG synthesis rates indirectly in cultures of
MPS IIIA and MPS VI cells (Roberts et al. 2006). Genistein
(5, 7-dihydroxy-3-[4-hydroxyphenyl]-4H-1-benzopyran-4-
one), a natural isoflavone occurring in many plants, sig-
nificantly inhibited GAG synthesis when added to cultures
of fibroblasts of MPS I, MPS II, MPS IIIA and MPS IIIB
patients (Piotrowska et al. 2006). In contrary to rhoda-
mine B, whose detailed mechanism of action remains
unknown, it was possible to learn about the way by which
genistein slows the GAG synthesis down. Epidermal
growth factor (EGF) is a ligand, whose binding by its
specific receptor (EGF receptor, EGFR) triggers a signal
transduction pathway resulting in the activation of
expression of certain genes, including those coding for
enzymes required for GAG synthesis. Genistein was
found to interfere with this pathway by inhibiting phos-
phorylation of EGFR (Jakobkiewicz-Banecka et al. 2009).
Therefore, the potential therapy based on the use of
genistein as an inhibitor of the EGF-mediated signal
transduction pathway has been named ‘gene expression-
targeted isoflavone therapy’ (GET IT) (Jakobkiewicz-
Banecka et al. 2009; Malinowska et al. 2009; Piotrowska
et al. 2011).
Specific silencing of expression of genes coding for
GAG synthetases is another mean of reducing the effi-
ciency of production of these compounds. In fact, two
strategies based on such an idea have been developed, both
employing the RNA interference (RNAi) mechanism. First,
short hairpin RNA (shRNA) molecules, specific to EXTL2
and EXTL3 genes, were used (Kaidonis et al. 2010). Sec-
ond, short interfering RNA (siRNA) oligonucleotides were
employed to reduce mRNA levels of four genes (XYLT1,
XYLT2, GALTI, and GALTII) whose products are required
for GAG synthesis (Dziedzic et al. 2010).
Efficacy of SRT in In Vitro Studies, Experiments
with Animal Models, and During Preliminary
Clinical Trials
Irrespective of which method was used to inhibit GAG
synthesis (treatment of cells with rhodamine B, genistein,
shRNA or siRNA), the results of experiments performed in
vitro with cell cultures or in vivo with animal models were
quite surprising. Namely, not only a reduced rate of GAGs
production and inhibition of their further accumulation was
observed but also a significant decrease in the storage was
evident. These studies are summarized briefly below.
Addition of rhodamine B into cultures of MPS IIIA and
MPS VI fibroblasts resulted in a significant decrease in
lysosomal storage of GAGs (Roberts et al. 2006). Rhoda-
mine B was administered to MPS IIIA mice at the dose of
1 mg/ml, and GAG levels were reduced relative to
untreated animals. Particularly, liver size, total GAG con-
tent, and lysosomal GAG were reduced as was urinary
GAG excretion. Lysosomal GAG content in the brain was
also significantly reduced by this treatment (Roberts et al.
2006). MPS IIIA mice treated with rhodamine B, in con-
trary to control MPS IIIA mice, improved performance
toward normal animals (Roberts et al. 2007).
Genistein at concentrations between 10 and 30 lM
inhibited GAG synthesis and reduced lysosomal GAG
storage (Piotrowska et al. 2006). Some other flavonoids
were also able to decrease GAG storage in MPS IIIA, IIIB,
and VII cells (Arfi et al. 2010; Piotrowska et al. 2010;
Kloska et al. 2011). Similar to rhodamine B, genistein
caused a marked improvement in treated MPS IIIB mice,
particularly in decreasing GAG storage in various organs
(Malinowska et al. 2009) and in correction of otherwise
severely changed behavior (Malinowska et al. 2010). The
same tendency of improvement was observed in MPS II
mice (Friso et al. 2010).
Lysosomal GAG levels were reduced in MPS I and MPS
IIIA fibroblasts treated with EXTL2- and EXTL3-specific
shRNAs (Kaidonis et al. 2010). Positive effects were also
observed in MPS IIIA cells in experiment with siRNA-
mediated silencing of expression of XYLT1, XYLT2, GAL-
TI, and GALTII genes (Dziedzic et al. 2010).
Efficacy in pre-clinical studies and a lack of toxicity of
genistein in experiments summarized above encouraged
researchers and clinicians to perform pilot clinical studies on
the use of GET IT in the treatment of patients suffering from
MPS. In the first open-label study, 10 patients diagnosed as
MPS IIIA or IIIB were treated for 12 months with a geni-
stein-rich soy isoflavone extract at the dose corresponding to
5 mg genistein/kg of body weight daily (Piotrowska et al.
2008). This treatment, in which no adverse effects were
noted, resulted in a statistically significant improvement in
all tested parameters (Piotrowska et al. 2008). Particularly,
urinary GAG levels were reduced, hair morphology (which
may be a useful parameter in monitoring efficacy of treat-
ment of patients suffering from various MPS types; Kloska
et al. 2005; Wegrzyn et al. 2007; Malinowska et al. 2008)
improved, and patients got higher scores in the psychological
test by which cognitive functions could be assessed
(Piotrowska et al. 2008). Nevertheless, one must note that the
positive changes were not dramatic, occurred in only a
fraction of patients, and the measured parameters did not
reach values estimated for healthy children. The 2-year fol-
low-up study generally confirmed a potential usefulness of
GET IT in the treatment of MPS III patients; however, it also
confirmed a limited efficacy of the treatment at least with the
use of low genistein doses (Piotrowska et al. 2011). Two
other studies with MPS III patients indicated that some dis-
ease-linked parameters and symptoms (like hair morphology
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and urinary GAG level) could be improved during GET IT
(Malinova et al. 2012), while changes in other parameters
(like a disability score) were not observed (Delgadillo et al.
2011). Nevertheless, results of very recent double-blinded
placebo-controlled clinical trial, which evaluated efficacy of
GET IT for MPS III, indicated that despite the fact that a
statistically significant decrease in GAG levels in urine and
plasma was found when genistein was administered at the
dose of 10 mg/kg/day, no statistically significant clinical
improvement could be observed during 6-month treatment
(de Ruijter et al. 2012). Therefore, it was suspected that
higher doses of genistein might be considerably more effi-
cacious (Wegrzyn 2012), especially since the most positive
effects were reported in mice at genistein dose of 160 mg/kg/
day (Malinowska et al. 2010), which is more than 10 times
higher than the highest dose used to date in published human
studies (Malinova et al. 2012). On the other hand, recent
clinical report indicated that not only MPS III but also MPS II
patients may potentially benefit from GET IT as a special
kind of SRT (Marucha et al. 2011). An important finding is a
lack of adverse effects in all the studies on SRT for MPS
reported to date and cited above.
Putative Mechanisms of SRT-Mediated Decreasing
of GAG Levels in MPS Cells
Results summarized in the preceding section, especially
those obtained in experiments with cell cultures and animal
models, were quite unexpected. Namely, based on the gen-
eral principle of SRT, one should expect rather inhibition or
slowing down of further accumulation of GAGs and thus,
slowing down the disease progress, rather than a decrease in
GAG storage and improvement of both MPS cells and ani-
mals. Therefore, the question appeared how could SRT lead
to GAG storage decrease?, which was especially unexpected
when two null alleles were present in genomes of affected
individuals. In fact, the studies described in the previous
section contained many such cases.
To answer this question, it is necessary to look at the
mechanism of GAG degradation, which is schematically
depicted in Fig. 1, showing HS degradation pathway as an
example. In the generally accepted model of breakdown of
this complex polysaccharide, there are sequential reactions
of either chemical modifications of the external sugar unit or
cutting off the whole external sugar unit. Therefore, if one of
the enzymes involved in the degradation process is deficient,
the whole pathway is blocked and undegraded metabolites
accumulate (for recent overviews and discussion, see We-
grzyn et al. 2010; Jakobkiewicz-Banecka et al. 2011).
α
Fig. 1 A scheme for degradation of heparan sulfate, with indicated
enzymes catalyzing particular reactions. Note that the picture is
schematic, and chemical moieties are not necessary presented with all
details. This scheme is based on figures published by Neufeld and
Muenzer (2001) and Wegrzyn et al. (2010)
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Fig. 2 The putative mechanisms of efficacy of SRT in the treatment
of MPS III. a A normal situation in a healthy cell, where intensive
GAG synthesis is in balance with effective GAG degradation (by
enzymes marked as E1, E2 and others; see Fig. 1 for the complete list
of these enzymes). b An MPS III cell, in which GAG accumulation
occurs due to dysfunction of enzyme E2. c–e Different putative
mechanisms of efficacy of SRT; namely, decrease of GAG storage
may results from: stop codon readthrough and appearance of small
amounts of the active enzyme E2 (c), cell growth and division which
causes GAG dilution (d), and/or activity of an unspecific GAG
endohydrolase (e.g., heparanase) and further degradation of some
GAG molecules despite enzyme E2 dysfunction (e). Note that these
mechanisms may be effective only when GAG synthesis is impaired
due to SRT. For details of this hypothesis, see text
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If GAG synthesis is inhibited, one may expect slowed
accumulation of the substrate that cannot be efficiently
degraded. However, if the defect of one of the enzymes
involved in GAG degradation is not complete and some
residual activity of such a protein is still present, it is likely
that the efficiency of GAG degradation will be high enough
to have additive effects towards its slow production. Then,
a decrease in total GAG level is not a surprise. However,
how to explain a GAG storage clearance if no residual
activity of a GAG-degrading enzyme is present?
We provide a hypothesis presenting three possible sce-
narios that may lead to a decrease in the amount of
accumulated GAGs in cells bearing two null alleles of a gene
coding for one of the enzymes involved in GAG degradation.
First, there is always a possibility of the leakiness of a null
mutation, especially if it is a non-sense mutation. In such a
case, the stop codon may be readthrough from time to time
(generally with a very low frequency), leading to appearance
of low amounts of a functional enzyme, able to degrade
already accumulated GAGs (Fig. 2c). However, this mech-
anism, although possible, would be rather of low efficiency,
thus it cannot serve as a sole explanation of the effects
described in the preceding section. Second, it should be
considered that cells used in experimental cultures are con-
stantly growing and dividing. This is true also for various
tissues of young animals used in studies as well as for chil-
dren taking part in clinical trials. Therefore, if GAG
synthesis is inhibited, the growing total cell volume would
result in decreasing total GAG concentration, the phenom-
enon actually observed (Fig. 2d). This, however, is unlikely
to operate in some cells and tissues, especially in neurons
forming the CNS. Nevertheless, there is a third possibility.
Namely, it is often forgotten that apart from exoglycosidases,
another class of enzymes, endoglycosidases, are involved in
GAG degradation. An example of such enzymes is hepa-
ranase that cleaves HS inside the chains, with the only,
though not strong, preference to low sulfation sites (for a
review, see Fux et al. 2009). Heparanase is located in lyso-
somes and at cell surface (Fux et al. 2009). One should take
into consideration that GAGs play their physiological roles
being linked to proteins, and thus, forming proteoglycans.
They are located at cell surface, and only those molecules
which are no longer required (including damaged ones) and
are devoted to degradation can be directed to lysosomes for
their hydrolysis. Hence, heparanase can potentially cleave
the GAG chain before and after it is transported into lyso-
some. It is likely that at certain frequency this enzyme can cut
the HS chain at the position just near the sugar monomer
which cannot be excised or modified (for example, by
removing the sulfate moiety) by the deficient hydrolase. In
such a case, other and still active hydrolases have open
access to their substrates, and previously blocked degrada-
tion of GAG can proceed (Fig. 2e).
We believe that each of the three putative mechanisms
described above, and especially their combination, may lead
to effects of a substantial decrease in GAG storage in various
cell types during SRT, observed in experiments. One should
note that efficiency of each of these mechanisms is too low to
overcome accumulation of GAGs in the absence of one of
specific exohydrolases when effective synthesis of these
compounds proceeds. Therefore, without inhibiting the
synthesis of GAGs, their storage is observed in MPS cells.
However, when GAG production is impaired due to SRT,
one can observe not only inhibition of further accumulation
of the stored material but also a decrease in the storage. This
phenomenon may be encouraging to perform further studies
on the use of SRT for MPS, as a potential therapy, possibly
able to help patients suffering from these severe diseases.
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